Overall Survival and Progression-free Survival

Slides:

Advertisements

Similar presentations

Moskowitz CH et al. Proc ASH 2014;Abstract 290.

Advertisements

Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

Lesokhin AM et al. Proc ASH 2014;Abstract 291.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

First-Line TKI Use in EGFR Mutation-Positive NSCLC

Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.

NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

Overall survival in NSCLC

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

이근욱 분당서울대학교병원/서울의대 혈액종양내과 부교수

R2 김재민 / Prof. 정재헌 Journal conference 1.

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

Julie Brahmer, M. D. , Karen L. Reckamp, M. D. , Paul Baas, M. D

¿Qué ver en ASCO 2017?.

Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology

Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.

1 Stone RM et al. Proc ASH 2015;Abstract 6.

Farletuzumab in platinum sensitive ovarian cancer with low CA125

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Rosell R et al. Proc ASCO 2011;Abstract 7503.

Presented By Michael Lee at 2016 ASCO Annual Meeting

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

Improved diagnosis, therapy and outcomes for patients with CUP

Bladder Cancer: A New Era in Treatment

LUCIE Localised Urothelial Carcinoma Immuno-oncology Evaluation Randomised Phase II trial, evaluating safety and efficacy of a combination therapy of.

Intervista a Lucio Crinò

Nat. Rev. Clin. Oncol. doi: /nrclinonc

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Distinct baseline tissue biomarkers are associated with response to nivolumab and ipilimumab in melanoma: CheckMate 064 Scott J. Rodig,1,2 Daniel Gusenleitner,2.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Information for participating Sites

Discussion Outline Cells of the Immune System.

Immunotherapy Combinations for Lung Cancers

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Figure 5 Schematic illustration of different clinical trial designs

Metastatic Renal Cell Carcinoma

Updates in Lung Cancer: Insights From Vienna

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Activity Goals. Activity Goals Discussion Topics.

Coiffier B et al. Proc ASH 2010;Abstract 857.

Jonathan W. Friedberg M.D., M.M.Sc.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Salles GA et al. Proc ASCO 2010;Abstract 8004.

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Baselga J et al. SABCS 2009;Abstract 45.

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Domenica 03 giugno Highlight a cura di Filippo de Marinis

Background: Gene Expression

Published online September 20, 2017 by JAMA Surgery

Adjuvant Therapy in Melanoma

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Figure 3 Determination of the primary site

CUP is a clinico-pathological syndrome of many specific cancer

Empiric versus Site-Directed Chemotherapy in Cancer of Unknown Primary

Coiffier B et al. Proc ASH 2011;Abstract 265.

Esteller, New England Journal of Medicine, 2008

Josep M. Llovet, Robert Montal, Augusto Villanueva

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

Presentation transcript:

Overall Survival and Progression-free Survival Hayashi et al., J Clin Oncol 2019

Forest Plot for Hazard Ratios of Site-specific Treatment versus Paclitaxel/Carboplatin Hayashi et al., J Clin Oncol 2019

Overall Survival and Progression-free Survival Hayashi et al., J Clin Oncol 2019

Overall Survival and Progression-free Survival Hayashi et al., J Clin Oncol 2019

Clinical Trials Clinical Trials CUPISCO To compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in patients with newly diagnosed unfavorable cancer of unknown primary site CheCUP To evaluate the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy

Panel Sequencing of CUP Cases About 30% of CUP samples contain potentially druggable genetic alterations at evidence levels 2/3 14% of CUP samples show high tumor mutational burden levels (TMB ≥ 16 Mut/Mb) (n=150) Ross, J.S., et al. (2015) JAMA Oncol 1:40-9; Löffler, et al. (2016) Oncotarget; Varghese et al., (2017) Ann Oncol; Gay et al., (2017) ASCO

in patients with newly diagnosed poor-risk CUP CUPISCO - Study Design International phase II, randomized, active-controlled, multicenter study comparing efficacy and safety of targeted or immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with newly diagnosed poor-risk CUP

CUPISCO - Timelines

CUPISCO – Participating Countries

CUPISCO – Recruitment Status and News Entrectinib added for NTRK and ROS1 fusions

CheCUP - Single Arm, Multicenter, Phase II Trial in Platinum-refractory CUP-Syndrome Nivolumab + Ipilimumab in platinum-refractory carcinoma of unknown primary Immune checkpoint inhibitor treatment with nivolumab + ipilimumab prolongs survival in patients with platinum-resistant CUP syndrome Tumor mutational burden predicts response to nivolumab + ipilimumab in patients with platinum-resistant CUP syndrome 6 Centers in Germany 194 Patients with platinum-refractory CUP Study starts in Q2 / 2019

Tumor Mutational Load Predicts Survival After Immunotherapy Across Multiple Cancer Types 1662 advanced cancer patiens treated with immune checkpoint inhibitors Tumor mutational burden in CUP (n=6116) Samstein et al., Nat Genet 2019 Gay et al., ASCO 2017

Summary Whether primary identification by gene expression profiling and tissue-of- origin specific treatment improves survival remains unclear Some caveats limit the interpretation of the Japanese GEP study (lymphomas, GEP assay, hard-to-treat cancers) Results of GEFCAPI 04 are awaited in 2019 CUPISCO: A large, international, randomized trial analyzing the impact of targeted treatments and immunotherapy in first-line unfavorable CUP has started in 2018 CheCUP: A national trial on the TMB-based impact of nivolumab + ipilimumab in second-line, platinum-refractory CUP will start in June 2019